Hummingbird Bioscience adds CBO to its leadership team

Singapore-based clinical-stage biotech Hummingbird Bioscience today announced the appointment of Angèle Maki, as chief business officer (CBO), with immediate effect.

Hummingbird noted that Dr Maki has two decades of experience in the biotech and pharma industry, with a track record of successful deals and partnerships across multiple therapeutic areas and modalities including significant numbers in antibody therapeutics. Most recently, she served as senior vice president and head of business development at ReCode Therapeutics, where she led business development, corporate development, investor and public relations. At ReCode Therapeutics, she was part of the team that raised a $120 million series B extension.

Prior to ReCode, Dr Maki held business development roles with increasing responsibility starting at Medarex, which was acquired by US pharma major Bristol Myers Squibb (NYSE: BMY), Genentech, Merck & Co (NYSE: MRK) and Eli Lilly (NYSE: LLY).